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Abstract
Background and Aim: Edible bird’s nest (EBN) is the nutrient-rich salivary bioproduct produced by swiftlets in Southeast 
Asia. Currently, researchers are exploring the therapeutic effects of EBN, such as cell growth promotion, antioxidant 
content, antiviral effects, bone strengthening, eyes care, and neuroprotection bioactivities. The therapeutic effects of EBN 
have been studied through different extraction methods but the metabolites profile of the EBN in each extract has not yet 
been elucidated. This study aimed to profile the water-soluble metabolites of EBN prepared in different extraction methods. 
Subsequently, an extraction method will be selected as an ideal extraction method for untargeted metabolite profiling on the 
water-soluble metabolites in EBN.
Materials and Methods: In this study, water-soluble metabolites of EBN extracted by the four extraction methods were 
subjected to metabolite profiling through liquid chromatography-mass spectrometry (LC-MS). The extraction methods were 
acid extraction(ABN), pancreatic extraction (EzBN), eHMG extraction, and spray drying of HMG extraction (pHMG). The 
metabolite profiles, such as the number of metabolites and their identities in each extraction method, were evaluated through 
LC-MS analysis.
Results: The identity of metabolites present in the four extraction methods is inconsistent. Based on LC-MS analysis, only 
one and six metabolites were extracted differently through EzBN and ABN, respectively, in the first pre-screening. Through 
the second LC-MS screening on pHMG and eHMG extraction methods, eHMG was selected as an ideal extraction method 
due to the highest numbers of water-soluble metabolites with an amount of 193 was detected. Besides, eHMG extraction 
method was able to extract sialic acid and a high percentage of secondary metabolites.
Conclusion: This study suggests that eHMG is the ideal extraction method for extracting higher number of water-soluble 
metabolites from EBN and could be further developed as an extraction method for industry application. In addition, this 
study also has identified the types of primary and secondary metabolites present in EBN.
Keywords: edible bird’s nest, extraction method, liquid chromatography-mass spectrometry, untargeted metabolite profiling.
Introduction
Edible bird’s nest (EBN) is a well-known 
bioproduct made from the saliva secretion of swift-
let, specifically from the two genera of Aerodramus 
and Collocalia. The swiftlet from the two genera is 
mostly habitat in Southeast Asia [1,2]. The main con-
stituents of EBN are proteins, carbohydrates, lipids, 
and a group of minerals such as calcium, sodium, 
potassium, magnesium, phosphorus, iron, zinc, cop-
per, chromium, and selenium [2-5]. EBN has been 
regarded as traditional Chinese medicine by the 
practitioners in Qing dynasty due to its recuperative 
properties [1,6]. The recuperative properties of EBN 
are highlighted with the effect of boosting immune 
system, treating malnutrition, improving metabolism, 
enhancing skin complexion and alleviating asthma, 
helping in phlegm clearance, relieving cough, nour-
ishing children, libido raising, enhancing renal func-
tion, recovery from illness and surgery, as well as 
improving concentration [7]. Recently, EBN is further 
demonstrated for its properties on suppressing the 
virus, inflammation and oxidative stress, strength-
ening bone, eye caring, and neuroprotective prop-
erties [8-14]. On the other hand, Roh et al. [15] and 
Kong et al. [16] have reported the proliferative effects 
of EBN on human adipose-derived stem cells and nor-
mal human fibroblasts with the presence of epidermal 
growth factor-like activity. In summary, EBN acts as a 
dual function bioproduct with both its nutritional and 
therapeutic values.
To study the constituents of EBN and its thera-
peutic effects, the development of an ideal extraction 
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methodology of EBN is very important. Several 
extraction methodologies were developed and used for 
studying the bioactivities of EBN. The study by Guo 
et al. [9] documented strong inhibition of influenza 
viruses by EBN extract that is pre-treated with pan-
creatin. Besides, Abidin et al. [11] also reported that 
the EBN extract prepared by eHMG extraction method 
successfully stimulated and enhanced the proliferation 
of corneal keratocytes in wound healing without alter-
ing their functionality. Chua et al. [17] prepared EBN 
extracts by the water extraction method (HMG). These 
extracts exhibited strong chondroprotective effects 
on osteoarthritis (OA). In addition, Aswir and Wan 
Nazaimoon [18] have documented acid-extracted EBN 
exhibited an anti-inflammation effect by significantly 
reducing the production of the inflammatory protein, 
tumor necrosis factor-alpha. In view of all the works, it 
is observed that different EBN extract obtained through 
different extraction methods showed different thera-
peutic effects. One possible explanation is because the 
extraction of an active component is highly dependent 
on the extraction method employed. Thus far, the iden-
tity of the metabolites in each of these extractions has 
not yet been further studied for the underlying mech-
anism of actions for their therapeutic effects. Hence, 
future study could be carried out to confirm the thera-
peutic effects of the metabolites.
Metabolite profiling is a powerful scientific tool 
for a complete investigation of a group of small mole-
cules. This approach often used in analyzing biological 
components for the identification of potential biomark-
ers for certain diseases [19]. Recently, metabolite pro-
filing has gained fame in food classification [20,21]; 
this is due to its untargeted analysis approach with the 
potential to cover the whole or the maximum metab-
olomics molecular information of foods. One of the 
examples of using the metabolite profiling approach 
on EBN has successfully demonstrated in the study 
done by Chua et al. [22]. The metabolites of the EBN 
were extracted through the chloroform/methanol sol-
vent extraction, which was then successfully identified 
through gas chromatography-mass spectrometry (MS) 
and liquid chromatography-MS (LC-MS) techniques.
Since water is commonly used to prepare EBN 
essence for consumption and the metabolites of 
EBN are not fully established yet, this study aimed 
to preliminary profile the water-soluble metabolites 
of EBN prepared in different extraction methods. 
Subsequently, an extraction method will be selected 
as an ideal extraction method for untargeted metabo-
lite profiling on the water-soluble metabolites in EBN.
Materials and Methods
Ethical approval
The study did not involve any live animals, so no 
ethical approval was required.
Chemicals
LC-MS grade formic acid and acetonitrile were 
purchased from Fisher Scientific (Waltham, MA, 
USA). Deionized water was obtained from a Barnstead 
GenPure water purification system (Thermo Fisher 
Scientific Inc., Waltham, MA, USA).
Sample collection, preparation, and extraction
Raw unclean EBNs samples were collected col-
lectively from different swiftlet premises located in 
Johor, Malaysia. The feathers and impurities were 
manually removed with forceps, and the raw unclean 
EBN was ground with mortar and pestle. Ground 
EBN was sieved through a 0.4 mm wire mesh to fur-
ther separate the smaller pieces of feathers and impu-
rities. The unclean EBN powder was then placed in 
an air force oven at 50-55°C overnight to reduce the 
moisture content.
There were four extraction methods selected for 
the comparison in this study, namely, eHMG, pHMG, 
ABN, and EzBN extraction methods. The raw unclean 
EBN was extracted with the proprietary methods of 
eHMG [11] and pHMG (the spray-dried of HMG 
extract) [17] that were innovated and standardized 
by School of Chemical and Energy Engineering in 
Universiti Teknologi Malaysia (UTM). These meth-
ods were modified based on the methods presented by 
Oda et al. [23] and Goh et al. [24]. Besides, another 
acid extraction (ABN) and pancreatin extraction 
(EzBN) were developed by the team of Universiti 
Tunku Abdul Rahman (UTAR) in 2016 [25] with 
some modification from the methods presented by 
Aswir and Wan Nazaimoon [18] and Goh et al. [9].
eHMG and pHMG
Due to the proprietary issue on these two 
extraction methods, the details of these two methods 
were unable to be described in this report.
Acid extraction (ABN)
The EBN powder was suspended in deionized 
water at 0.2% (w/v) and left for 24 h. The mixture was 
then boiled at 80°C with 2% (v/v) of 0.4 M sulfuric 
acid for 4 h. The extract was allowed to cool down and 
centrifuged at 2716 g (5000 rpm) for 15 min. The pH 
of the supernatant collected was neutralized to pH 7.0. 
The white precipitated formed was removed through 
centrifugation with 2716 g (5000 rpm) for 15 min at 
4°C. The supernatant was collected and kept at 4°C 
for further analysis.
Pancreatin extraction (EzBN)
The EBN powder was suspended in deionized 
water at 0.2% (w/v) and left for 24 h. The EBN mix-
ture was boiled at 100°C for 30 min. An amount of 
1 ml of 0.5 mg/ml pancreatin was added into EBN 
mixture and was allowed for the reaction at 45°C for 
4 h with pH 8.5-9.0. The enzyme was inactivated by 
heating at 90°C for 10 min. The supernatant was col-
lected after centrifugation at 2716 g (5000 rpm) for 
15 min. The extract was kept at 4°C.
Before subjecting the extracts to LC-MS anal-
ysis, all the four extracts were centrifuged at 9660 g 
Veterinary World, EISSN: 2231-0916 306
Available at www.veterinaryworld.org/Vol.13/February-2020/12.pdf
(12,000 rpm) for 10 min and the supernatant of the 
extracts was filtered through 0.2 µm polytetrafluoro-
ethylene membranes.
Quadrupole time-of-flight (QTOF) LC-MS analysis
The four EBN extracts were qualitatively 
analyzed using Agilent 6560 Ion Mobility QTOF 
(IM-QTOF) LC-MS system that coupled with the 
Agilent 1290 ultra-high-performance liquid chroma-
tography (Agilent Technologies, USA). The metab-
olites present in the EBN extracts were separated 
through POROSHELL 120 EC-C18 (4.6×100 mm; 
2.7 μ; Agilent Technologies, USA) chromatographic 
column with the mobile phase that consisted of (A) 
0.1% formic acid in water and (B) 0.1% formic 
acid in acetonitrile. All the four EBN extracts were 
undergone the first pre-screening evaluation with the 
elution of 5-95% B (0.0-1.0 min) and 95-5% B (1.0-
15.0 min). The flow rate was set at 1.0 ml/min. The 
two extracts with a higher number of metabolites were 
selected and further subjected for the second LC-MS 
screening with modified mobile phase elution. The 
condition of the modified elution was set as follows: 
5% B (0.0-2.0 min), 5-15% B (2.0-4.0 min), 15-25% 
B (4.0-6.0 min), 25-35% B (6.0-8.0 min), 35-45% B 
(8.0-10.0 min), 45-50% B (10.0-12.0 min), 50-75% B 
(12.0-16.0 min), 75-100% B (16.0-20.0 min), 100-5% 
B (20.0-20.1 min), and isocratic at 5% (20.1-25 min). 
The flow rate was modified to 0.3 ml/min.
The other setting parameters for IM-TOF 
analysis remained the same throughout the analysis 
process. The injection volume was 1 µl and the column 
temperature was maintained at 40°C. The acquisition 
of the metabolites was performed in positive (ES+) 
mode. The mass spectra were recorded over an m/z 
range from 100 to 1000. Deionized water was used 
as the background blank. Whereas, the operating con-
ditions of the mass spectrometer were set as follows: 
Capillary voltage of 4000 V, nozzle voltage of 500 V, 
and fragmentor voltage of 365 V were maintained. 
Nebulizer pressure (N2) was kept at 20 psi, drying 
gas temperature was maintained at 225°C. Drying gas 
flow was 13 L/min and sheath gas flow was 12 L/min 
at 400°C.
Data mining and metabolites identification
The metabolite features from the acquired MS 
spectral raw data were extracted with the untargeted 
molecular feature extraction algorithm in Agilent 
MassHunter Workstation - Qualitative Analysis soft-
ware B.07.00 (Agilent Technologies, USA). The algo-
rithm filtered off the peak height with 100 counts to 
avoid the noise spectral picking, as well as the mass of 
internal reference ions with 121.0967 and 922.1389. 
Then, the algorithm locates the covariant ions in the 
chromatogram and grouped them as a single metab-
olite feature using the information of mass, isotopic 
distribution with common organic elements (C, H, O, 
N, P, Cl, F, and S), charge-state and adducts of sodium, 
potassium, and ammonium. The extracted metabolite 
features were characterized by retention time (RT) 
and intensity.
The identity of the extracted metabolite features 
was searched against METLIN Personal Metabolite 
Database in the MassHunter software based on the 
accurate mass and RT (optional). The mass and RT 
tolerance of the compound identity matching was 
restricted to ±5 ppm and ±0.1 min (optional), respec-
tively. The accuracy of the identity of each metabolite 
was calculated as a score. The metabolites list of each 
extract was retained if the identity of the metabolite 
fulfilled the threshold score of 80, and the error of 
database matching was less than ±5 ppm.
Results and Discussion
The efficiency of EBN extraction methods
The method of extraction is a crucial process that 
maximizes the extraction of the bioactive metabolites 
from EBN. To search for an ideal extraction method 
for the untargeted metabolite profiling of EBN, four 
different extraction methods with the therapeutic 
effects were assessed and evaluated. For example, 
pancreatin extraction with antiviral effect as reported 
by Guo et al. [9]; eHMG extraction with the effect 
of enhancing proliferation of corneal keratocytes by 
Abidin et al. [11]; HMG extraction showed chon-
droprotective effect on OA as documented by Chua 
et al. [17]; and finally the acid extraction with anti-in-
flammation bioactivities reported by Aswir and Wan 
Nazaimoon [18]. The approach of LC-MS is recog-
nized with its high sensitivity, accuracy, and reproduc-
ibility [26-28]; thus, there was no technical replicate 
done in this untargeted metabolite profiling analysis.
The number of detected metabolites in each of the 
extraction method was analyzed by MassHunter soft-
ware. Nearly 37-67% out of the total metabolites from 
the four different extracts were putatively identified 
by matching with the METLIN metabolites database. 
The complete information of all the identified metab-
olites in each extraction method is detailed in Table-1. 
The identities of the extracted metabolites are unique 
among the four different extracts, suggesting that there 
is no single extraction method that could extract all 
types of metabolites due to the differences in natural 
physicochemical properties of the metabolites [29-32].
Based on the mobile phase for compound sep-
aration in the first screening evaluation, there were 
significant differences in the number of extracted 
metabolites under each extraction method (Table-2a). 
The highest total number of metabolites obtained was 
from pHMG extract and followed by eHMG extract. 
The total number of metabolites detected in both of 
pHMG and eHMG extracts was greater than EzBN 
and ABN extracts, with approximately 20-30 times 
and 4-5 times, respectively. However, the LC-MS 
separation for each extract was not well defined by 
referring to the chromatograms obtained (Figure-1). 
Therefore, the second screening evaluation was 
carried out with an improved LC-MS mobile phase. 
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Table-1: Information of the metabolites in each extracts with first pre-screening by QTOF LC-MS.
Number RT (min) Ion Mass m/z Molecular 
formula





1 1.001 (M+NH4)+ 104.0375 122.0713 C6H4N2 85.65 −0.48 4-Cyanopyridine
2 1.005 (M+H)+ 273.1082 274.1154 C9H15N5O5 97.11 −3.06 4a-Peroxy-tetrahydrobiopterin
3 1.005 (M+H)+ 291.1206 292.1278 C14H17N3O4 89.12 4.47 Serinyl-Tryptophan
4 1.005 (M+H)+ 309.1332 310.1406 C17H18F3NO 87.45 2.62 Fluoxetine
5 1.039 (M+Na)+ 325.0796 348.0687 C14H15NO8 84.49 0.49 Pancratistatin
6 1.083 (M+Na)+ 291.0943 314.0835 C11H17NO8 95.46 3.83 2-Deoxy-2,3-dehydro-N-
acetylneuraminic acid
EzBN
1 1.502 (M+H)+ 109.0643 110.0715 C5H7N3 85.25 −2.46 2-Aminomethylpyrimidine
eHMG
1 0.741 (M+H)+ 379.1125 380.1197 C14H21NO11 83.05 −2.62 Chondroitin
2 0.924 (M+Na)+ 333.1523 356.1415 C13H23N3O7 80.80 3.82 Ser Asp Leu
3 1.007 (M+H)+ 385.2081 386.2152 C15H27N7O5 83.05 −1.87 Asn Pro Arg
4 1.042 (M+H)+ 311.1692 312.1764 C12H21N7O3 91.60 4.34 Arginyl-Histidine
5 1.112 (M+H)+ 344.2172 345.2244 C14H28N6O4 84.88 0.07 Gly Ile Arg
6 1.138 (M+NH4)+ 384.2144 402.2484 C20H32O7 81.25 1.10 Cinnzeylanol
7 1.311 (M+H)+ 387.2238 388.2313 C15H29N7O5 94.39 −2.03 Arg Asn Val
8 1.383 (M+H)+ 373.2333 374.2405 C16H31N5O5 81.27 −2.19 Lys Asn Leu
9 4.299 (M+H)+ 654.3986 655.4060 C35H58O11 93.38 −1.00 Filipin III
10 4.316 (M+H)+ 130.0741 131.0813 C5H10N2O2 87.43 1.25 L-cis-3-Amino-2-
pyrrolidinecarboxylic acid
11 4.342 (M+H)+ 114.0433 115.0505 C4H6N2O2 86.61 −3.03 Muscimol
pHMG
1 1.019 (M+H)+ 166.0270 167.0344 C8H6O4 85.71 −2.59 3-Formylsalicylic acid
2 1.020 (M+Na)+ 383.1430 406.1321 C14H25NO11 98.38 −0.64 Lacto-N-biose I
3 1.022 (M+Na)+ 309.1065 332.0956 C11H19NO9 82.57 −1.76 N-Acetyl-b-neuraminic acid
4 1.023 (M+Na)+ 325.0792 348.0685 C14H15NO8 82.22 1.85 Pancratistatin
5 1.024 (M+H)+ 203.0798 204.0870 C8 H13NO5 86.39 −1.97 N2-Acetyl-L-aminoadipate
6 1.026 (M+Na)+ 291.0960 314.0851 C12H13N5O4 84.24 2.72 Toyocamycin
7 1.075 (M+Na)+ 291.0954 314.0847 C11H17NO8 83.71 0.12 2,7-Anhydro-alpha-N-
acetylneuraminic acid
8 1.314 (M+H)+ 137.0478 138.0551 C7H7NO2 87.40 −1.17 2-Pyridylacetic acid
9 1.319 (M+Na)+ 145.0770 168.0660 C9H9N2 81.66 −2.63 4-Aminomethylindole
10 1.402 (M+H)+ 245.1385 246.1457 C10H19N3O4 81.33 −3.66 Asn Leu
11 1.514 (M+H)+ 135.0544 136.0617 C5H5N5 84.12 0.94 Adenine
12 1.542 (M+NH4)+ 256.0582 274.0920 C11H12O7 93.89 0.53 Piscidic Acid
13 5.692 (M+H)+ 101.0840 102.0912 C5H11NO 87.59 0.67 2-Methylpropanal 
O-methyloxime
RT=Retention time, DB=Database, LC-MS=Liquid chromatography-mass spectrometry, QTOF=Quadrupole time-of-flight
Table-2: Number of metabolites detected and identified by QTOF LC-MS in each of the extracts for the first pre-
screening and the second screening with the optimized LC-MS parameters.
Extracts Total metabolites Putatively identified metabolites Metabolites after filtering*
(a) First pre-screening
ABN 18 7 6
EzBN 3 2 1
eHMG** 69 26 11
pHMG** 85 34 13
(b) Second screening with optimized parameters
eHMG 775 468 193
pHMG 168 96 42
*Metabolites filtering is based on the presence of contaminants, the score and database matching error (ppm). **The 
extracts were selected for the second screening with the optimized LC-MS parameters. LC-MS=Liquid chromatography-
mass spectrometry, QTOF=Quadrupole time-of-flight
Both of the eHMG and pHMG extraction methods 
were selected to undergo the second screening evalu-
ation since they showed greater efficacy in extracting 
the higher number of metabolites from EBN in the 
first screening evaluation.
The second screening evaluation with an 
optimized LC-MS mobile phase for separating com-
pounds has greatly improved the elution efficacy 
and increased the number of analyzed metabolites 
(Figure-2a and b). The good separation in the liquid 
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chromatography has broadened the range of eluted 
metabolites. Hence, the second screening evalua-
tion has provided a better comparison between the 
eHMG and pHMG extraction methods. The eHMG 
extraction method has successfully recovered a sig-
nificant number in total extracted metabolites as 
compared with pHMG (Table-2b). There were 193 
metabolites detected from eHMG extraction method 
(Table-2b), which are more than 26 non-polar metab-
olites detected in the study done by Chua et al. [22]. 
Therefore, the eHMG extraction method was selected 
as the ideal extraction method because it provided 
the maximal recovery of the number of water-soluble 
metabolites present in EBN.
The metabolite profile of extraction methods
In the second screening evaluation, there were 
approximately more than half out of the total metabo-
lites (60.39% and 57.14% of metabolites, respectively) 
from eHMG and pHMG extracts that were putatively 
identified. The information of the retained metabolites 
for both eHMG and pHMG extraction methods in the 
second screening evaluation are shown in Tables-3 
and 4, respectively. Based on the comparison between 
eHMG and pHMG extraction methods in the second 
screening evaluation, 24 out of the total identified 
metabolites were found to be similar in each extract 
(Figure-2c). The result indicated that the eHMG 
extraction method not only extracted a greater num-
ber of metabolites but also there were approximately 
57.14% of the metabolites from pHMG extraction 
method which were found to be similar to eHMG. The 
identities of the metabolites that found to be similar in 
both of the extraction methods are marked in Tables-3 
and 4.
Sialic acid is known as the key component of 
EBN because it is served as the unique quantitative 
marker for grading the EBN. In this study, sialic acid 
was identified in the eHMG extraction method with the 
identity of 2,7-Anhydro-alpha-N-acetylneuraminic 
acid (Table-3). The result agreed with the previous 
studies that N-acetylneuraminic acid (NANA) is the 
predominant form of sialic acid in EBN [33-35]. The 
Figure-1: Total ion chromatograms of the first liquid chromatography/mass spectrometry (LC-MS) pre-screening on edible 
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Figure-2: The second liquid chromatography/mass spectrometry (LC-MS) screening with optimized parameters on eHMG 
and pHMG extracts. (a) Total ion chromatograms of eHMG and pHMG extraction methods selected from the first pre-
screening. The LC-MS chromatograms were obtained from ES+mode. (b) The efficiency comparison between the first and 
second screening for both eHMG and pHMG extracts. (c) The number of metabolites that found similar between pHMG 
and eHMG extracts. The comparison was made based on the identified metabolites that the contaminant was filtered off. 
(d) The classification of edible bird’s nest metabolites in eHMG and pHMG extracts. The classification was based on the 
metabolite identities after removing the contaminants.
detected of sialic acid in eHMG extract has further 
convinced that eHMG extraction method is more suit-
able as the ideal extraction method.
The type of metabolites present in eHMG and 
pHMG extracts (from the second screening) was 
















1 7.678 (M+NH4)+ 188.1052 206.1388 C9H16O4 87.23 −1.78 (+/−)-Ethyl 
3-acetoxy-2-methylbutyrate
2 6.351 (M+H)+ 156.0533 157.0605 C6H8N2O3 86.21 1.11 (S)-3-(Imidazol-5-yl)lactate
3 9.285 (M+NH4)+ 146.0481 164.0819 C8H6N2O 87.68 −0.82 1(2H)-Phthalazinone
4 7.814 (M+H)+ 225.1118 226.1190 C10H15N3O3 85.52 −1.99 1-(Methylnitrosoamino)-4-
(3-pyridinyl)-1,4-butanediol
5 7.154 (M+NH4)+ 151.1003 169.1341 C9H13NO 85.35 −3.75 1,2,3,4,5,6-Hexahydro-5-
methyl-7H-cyclopenta[b]
pyridin-7-one
6 19.916 (M+H)+ 310.2875 311.2947 C20H38O2 82.62 −1.10 15Z-eicosenoic acid
7 19.852 (M+NH4)+ 168.1882 186.2220 C12H24 93.33 −2.37 1-Dodecene*
8 17.086 (M+H)+ 203.0811 204.0882 C9H17NS2 90.55 −4.19 1-Isothiocyanato-7-
(methylthio)heptane*
9 13.104 (M+H)+ 115.0456 116.0528 C5H9NS 95.32 −0.49 1-Isothiocyanatobutane*
10 19.913 (M+NH4)+ 392.4382 410.4720 C28 H56 95.74 0.02 1-Octacosene*
11 8.497 (M+Na)+ 303.1824 326.1717 C18H25NO3 93.54 3.33 1-O-Desmethyltetrabenazine
12 6.266 (M+H)+ 129.0429 130.0503 C5H7NO3 94.98 −2.57 1-Pyrroline-4-hydroxy-2-
carboxylate




14 15.590 (M+H)+ 171.1087 172.1160 C9H17NS 90.62 −3.11 2,5-Dihydro-4,5-dimethyl-2-
(1-methylpropyl)thiazole*
15 7.631 (M+H)+ 291.0958 292.1030 C11H17NO8 98.24 −1.31 2,7-Anhydro-alpha-N-
acetylneuraminic acid
16 8.822 (M+NH4)+ 418.1835 436.2172 C19H30O10 98.30 1.05 2-[4-(3-Hydroxypropyl)-
2-methoxyphenoxy]-1,3-
propanediol 1-glucoside
17 8.685 (M+H)+ 113.0843 114.0917 C6H11NO 86.02 −2.34 2-Acetylpyrrolidine*
18 5.701 (M+NH4)+ 155.0950 173.1288 C8H13NO2 86.86 −2.51 2-Amino-2-
Norbornanecarboxylic acid
19 5.702 (M+H)+ 190.0958 191.1029 C7H14N2O4 90.69 −2.50 2-Amino-4-[(2-hydroxy-1-
oxopropyl)amino]butanoic 
acid
20 7.725 (M+NH4)+ 239.1067 257.1405 C14H13N3O 81.23 −3.70 2-amino-a-phenyl-1H-
Benzimidazole-5-methanol
21 10.087 (M+NH4)+ 94.0785 112.1124 C7H10 86.34 −2.46 2-Methyl-1,3-cyclohexadiene
22 7.103 (M+H)+ 155.0701 156.0774 C6H9N3O2 84.30 −4.09 3-(Pyrazol-1-yl)-L-alanine
23 6.949 (M+NH4)+ 118.0421 136.0759 C8H6O 87.41 −1.96 3,5,7-Octatriyn-1-ol





25 9.346 (M+H)+ 186.1374 187.1449 C9H18N2O2 96.27 −3.33 3-[(3-Methylbutyl)
nitrosoamino]-2-butanone
26 6.347 (M+NH4)+ 129.0791 147.1129 C6H11NO2 99.35 −0.98 3-acetamidobutanal
27 7.395 (M+H)+ 194.1061 195.1134 C10H14N2O2 85.27 −2.80 3-Hydroxy-N-
glycyl-2,6-xylidine 
(3-Hydroxyglycinexylidide)
28 7.632 (M+H)+ 196.0377 197.0449 C9H8O5 85.10 −2.44 3-Methoxy-4,5-
methylenedioxybenzoic acid
29 19.921 (M+NH4)+ 278.2972 296.3311 C20H38 85.63 0.46 3Z,6Z-Eicosadiene
30 10.783 (M+H)+ 218.1424 219.1495 C13H18N2O 92.62 −2.42 4-[2-(Propylamino)ethyl]-
1,3-dihydro-2H-indol-2-one
31 7.627 (M+Na)+ 145.0766 168.0658 C9H9N2 86.63 0.02 4-Aminomethylindole
32 8.253 (M+NH4)+ 153.1156 171.1493 C9H15NO 92.51 −1.46 4-Butyl-2,5-dimethyloxazole
33 5.641 (M+NH4)+ 167.1316 185.1654 C10H17NO 85.56 −3.51 4-Butyl-2-ethyl-5-
methyloxazole
34 10.175 (M+H)+ 104.0373 105.0446 C6H4N2 87.29 1.25 4-Cyanopyridine
35 8.933 (M+H)+ 466.2196 467.2267 C19H30D3N3O8S 87.39 −4.25 4-hydroxy Nonenal 
Glutathione-d3
36 6.351 (M+H)+ 166.0379 167.0452 C7H6N2O3 83.68 −0.52 4-Hydroxy-3-
nitrosobenzamide
37 8.457 (M+NH4)+ 129.0430 147.0769 C5H7NO3 96.21 −2.91 4-Oxoproline*
Table-3: Information of the metabolites in eHMG extract. The metabolites are identified by QTOF LC-MS with second 
screening evaluation.
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38 6.327 (M+NH4)+ 168.0903 186.1241 C8H12N2O2 86.78 −2.26 4-PIOL
39 8.928 (M+NH4)+ 139.0638 157.0977 C7H9NO2 86.17 −3.48 5-Acetyl-2,4-dimethyloxazole
40 7.722 (M+NH4)+ 267.1016 285.1354 C15H13N3O2 81.08 −3.24 5-benzyl-5-(pyridin-3-yl)
imidazolidine-2,4-dione
41 7.815 (M+NH4)+ 165.1159 183.1497 C10H15NO 98.24 −3.05 5-Methyl-2-(1-pyrrolidinyl)-
2-cyclopenten-1-one*
42 7.400 (M+H)+ 241.1067 242.1140 C10H15N3O4 86.34 −1.88 5-Methyldeoxycytidine
43 9.361 (M+Na)+ 597.3489 620.3383 C31H51NO10 89.94 4.09 5-O-β-D-
Mycaminosyltylonolide
44 7.658 (M+NH4)+ 139.0999 157.1337 C8H13NO 92.23 −1.66 5-Pentyloxazole
45 7.406 (M+H)+ 172.0851 173.0924 C7H12N2O3 97.82 −1.94 5-δ-Hydroxybutyl Hydantoin
46 8.150 (M+Na)+ 585.2945 608.2836 C33H39N5O5 91.39 1.04 8’,10’- 
Dihydroxydihydroergotamine
47 6.927 (M+H)+ 216.0755 217.0829 C8H12N2O5 95.52 −4.14 8-Hydroxyalanylclavam
48 7.919 (M+NH4)+ 228.1364 246.1703 C12H20O4 86.63 −1.26 9,12-dioxo-dodecanoic acid
49 16.039 (M+NH4)+ 250.2300 268.2639 C17H30O 86.18 −1.19 9S,10R-Epoxy-3Z, 
6Z-octadecadiene*
50 19.926 (M+NH4)+ 364.4068 382.4407 C26H52 99.78 0.22 9Z-Hexacosene*
51 6.756 (M+NH4)+ 217.0856 235.1194 C11H11N3O2 86.25 −2.08 Acetylhydrazinopthalazinone
52 9.279 (M+NH4)+ 245.1170 263.1508 C13H15N3O2 96.87 −2.15 Acetyltryptophanamide
53 4.538 (M+H)+ 135.0551 136.0623 C5H5N5 84.51 −4.22 Adenine*
54 7.198 (M+H)+ 243.1221 244.1298 C10H17N3O4 85.40 −0.95 Ala Gly Pro
55 6.934 (M+NH4)+ 236.1165 254.1504 C12H16N2O3 97.31 −1.88 Alanyl-DL-Phenylalanine
56 3.734 (M+H)+ 226.1074 227.1145 C9H14N4O3 87.75 −3.48 Alanyl-Histidine*
57 8.374 (M+H)+ 232.1578 233.1652 C14H20N2O 85.03 −0.85 Albine
58 6.159 (M+NH4)+ 141.0796 159.1134 C7H11NO2 85.48 −4.19 Arecaidine
59 7.686 (M+H)+ 271.1650 272.1723 C11H21N5O3 86.06 −1.91 Arginyl-Proline
60 7.155 (M+H)+ 279.1216 280.1289 C13H17N3O4 85.73 1.14 Asn Phe
61 9.361 (M+NH4)+ 378.1906 396.2245 C18H26N4O5 99.55 −0.62 Asn Val Phe
62 5.759 (M+H)+ 368.1330 369.1404 C15H20N4O7 84.38 0.41 Asn-Lys-OH
63 3.515 (M+Na)+ 349.1122 372.1015 C12H19N3O9 98.31 −0.19 Asp Thr Asp
64 7.189 (M+Na)+ 559.3144 582.3037 C31H45NO8 94.22 0.15 Auriculine
65 3.073 (M+NH4)+ 173.0434 191.0772 C5H7N3O4 87.00 1.51 Azaserine
66 14.410 (M+NH4)+ 290.1788 308.2126 C20H22N2 83.40 −1.75 Azatadine
67 4.411 (M+NH4)+ 472.2283 490.2622 C27H36O5S 93.08 0.12 BAY-u9773
68 7.655 (M+NH4)+ 165.0796 183.1135 C9H11NO2 85.21 −4.05 Benzocaine
69 9.276 (M+H)+ 234.1483 235.1557 C12H18N4O 94.24 −1.09 Benzoylagmatine
70 8.382 (M+Na)+ 365.1733 388.1628 C21H23N3O3 82.56 1.83 Brevianamide B
71 3.342 (M+H)+ 109.0644 110.0717 C5H7N3 96.49 −4.13 Brunfelsamidine*
72 8.118 (M+H)+ 643.3329 644.3407 C35H49NO10 80.90 4.29 Buprenorphine 
3-O-glucuronide
73 7.511 (M+NH4)+ 224.1165 242.1504 C11H16N2O3 84.08 −2.03 Butalbital
74 6.960 (M+H)+ 212.1166 213.1240 C10H16N2O3 80.31 −2.26 Butethal
75 6.757 (M+H)+ 278.1270 279.1342 C14H18N2O4 95.45 −1.14 Carboxy-PTIO
76 8.511 (M+H)+ 607.3124 608.3200 C31H41N7O6 90.53 −0.90 Chymostatin
77 17.086 (M+H)+ 127.1365 128.1437 C8H17N 86.60 −2.89 Coniine*
78 6.940 (M+H)+ 176.0947 177.1028 C10H12N2O 82.06 1.45 Cotinine
79 9.360 (M+Na)+ 203.1303 226.1195 C13H17NO 96.10 3.31 Crotamiton
80 9.356 (M+H)+ 224.1892 225.1965 C13H24N2O 93.91 −1.45 Cuscohygrine
81 7.537 (M+H)+ 244.1215 245.1287 C14H16N2O2 86.62 −1.11 Cyclo(L-Phe-L-Pro)
82 6.992 (M+H)+ 227.0914 228.0986 C9H13N3O4 95.88 −3.67 Deoxycytidine
83 9.360 (M+H)+ 249.1484 250.1556 C13H19N3O2 93.27 −2.74 Desethyl-N 
-acetylprocainamide
84 8.511 (M+H)+ 308.1534 309.1601 C19H20N2O2 86.91 −3.03 DMXB-A
85 5.307 (M+H)+ 115.0636 116.0709 C5H9NO2 92.37 −2.15 D-Proline
86 7.816 (M+H)+ 491.2724 492.2797 C27H41NO5S 86.49 −3.72 Epothilone D
87 6.928 (M+H)+ 204.0900 205.0974 C11H12N2O2 83.85 −0.71 Ethotoin
88 8.746 (M+NH4)+ 261.1004 279.1341 C14H15NO4 85.03 −0.98 Ethyl 1-benzyl-3-
hydroxy- 2-oxo[5H]
pyrrole-4-carboxylate
89 9.297 (M+NH4)+ 373.1958 391.2294 C15H27N5O6 83.01 0.87 Gln Asn Ile
90 6.351 (M+H)+ 300.1433 301.1505 C12H20N4O5 99.12 0.11 Gln Gly Pro
91 7.242 (M+H)+ 406.2211 407.2284 C20H30N4O5 81.92 1.31 Gln Leu Phe
92 9.361 (M+H)+ 421.2328 422.2402 C20H31N5O5 96.22 −0.75 Gln Phe Lys
93 7.815 (M+H)+ 356.2061 357.2133 C16H28N4O5 98.89 −0.50 Gln Pro Leu
94 7.150 (M+Na)+ 340.1749 363.1642 C15H24N4O5 84.85 −0.70 Gln Pro Pro
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95 6.983 (M+NH4)+ 462.1757 480.2096 C21H26N4O8 81.05 −1.42 Glu Trp Glu
96 7.169 (M+H)+ 172.0854 173.0927 C7H12N2O3 97.76 −3.55 Gly Pro
97 8.482 (M+NH4)+ 311.1121 329.1458 C13H17N3O6 82.80 −1.26 Gly-Lys-OH
98 14.553 (M+H)+ 273.2672 274.2746 C16H35NO2 95.51 −1.71 Hexadecasphinganine
99 18.610 (M+H)+ 101.1200 102.1273 C6H15N 84.30 3.97 Hexylamine*
100 5.759 (M+H)+ 226.1065 227.1137 C9H14N4O3 99.39 0.42 His Ala
101 8.072 (M+H)+ 302.1386 303.1461 C15H18N4O3 82.69 −2.51 His Phe
102 7.651 (M+H)+ 417.2011 418.2082 C20H27N5O5 96.58 0.17 His Tyr Val
103 7.209 (M+NH4)+ 348.1060 366.1397 C15H16N4O6 94.60 2.81 His-Ala-OH
104 8.180 (M+H)+ 302.1382 303.1453 C15H18N4O3 84.08 −1.15 Histidinyl-Phenylalanine
105 5.675 (M+NH4)+ 254.1383 272.1722 C11H18N4O3 98.61 −1.64 Histidinyl-Valine
106 6.641 (M+H)+ 259.1168 260.1239 C10H17N3O5 83.20 0.08 Hydroxypropyl-Gamma-
glutamate
107 7.566 (M+NH4)+ 268.1173 286.1510 C11H16N4O4 81.20 −0.36 Hydroxypropyl-Histidine
108 5.700 (M+Na)+ 289.1639 312.1534 C12H23N3O5 81.82 −0.36 Ile Ala Ser
109 7.815 (M+H)+ 259.1538 260.1611 C11H21N3O4 98.35 −2.20 Ile Gln
110 8.447 (M+H)+ 356.2061 357.2134 C16H28N4O5 94.09 −0.48 Ile Gln Pro
111 6.481 (M+NH4)+ 180.0538 198.0876 C8H8N2O3 85.24 −1.88 Isonicotinylglycine
112 18.618 (M+H)+ 298.1545 299.1616 C15H18N6O 87.32 −0.95 Iso-Olomoucine*
113 8.688 (M+NH4)+ 268.1315 286.1653 C14H20O5 95.31 −1.49 Kamahine C*
114 3.088 (M+NH4)+ 151.0606 169.0945 C5H11O5 83.97 0.54 L-(+)-Arabinose
115 9.360 (M+H)+ 210.1373 211.1445 C11H18N2O2 97.17 −2.43 L,L-Cyclo(leucylprolyl)
116 3.379 (M+Na)+ 383.1427 406.1318 C14H25NO11 82.74 0.16 Lacto-N-biose I*
117 6.715 (M+H)+ 196.1218 197.1292 C10H16N2O2 81.16 −3.27 L-alpha-Amino-1H 
-pyrrole-1-hexanoic acid
118 9.355 (M+H)+ 372.2377 373.2447 C17H32N4O5 84.53 −1.09 Leu Ile Gln
119 16.538 (M+H)+ 195.0538 196.0610 C9H9NO4 83.37 −3.51 Leucodopachrome
120 6.993 (M+H)+ 259.1905 260.1976 C12H25N3O3 80.87 −3.52 Leucyl-Lysine
121 8.258 (M+H)+ 280.1065 281.1142 C14H12N6O 81.98 2.63 Levosimendan
122 8.072 (M+H)+ 587.3072 588.3144 C32H45NO9 84.74 3.76 Lipomycin
123 9.360 (M+H)+ 252.1846 253.1918 C14H24N2O2 96.56 −3.25 Lupanyl Acid
124 7.815 (M+NH4)+ 396.2010 414.2348 C18H28N4O6 99.69 −0.28 Lys Ser Tyr
125 6.826 (M+H)+ 309.1685 310.1762 C15H23N3O4 87.90 1.22 Lys Tyr
126 4.413 (M+H)+ 233.1375 234.1451 C9H19N3O4 93.49 0.10 Lysinoalanine
127 7.814 (M+NH4)+ 293.1746 311.2084 C15H23N3O3 98.62 −2.09 Lysyl-Phenylalanine
128 7.162 (M+H)+ 309.1693 310.1766 C15H23N3O4 98.16 −1.39 Lysyl-Tyrosine
129 8.464 (M+NH4)+ 109.0530 127.0869 C6H7NO 84.94 −2.26 m-Aminophenol
130 3.516 (M+H)+ 114.0432 115.0504 C4H6N2O2 84.07 −2.51 Muscimol
131 8.440 (M+H)+ 517.2874 518.2948 C25H43NO10 96.46 2.44 Mycalamide B
132 7.630 (M+H)+ 203.0800 204.0871 C8H13NO5 95.68 −2.92 N2-Acetyl-L-aminoadipate
133 7.512 (M+H)+ 130.1109 131.1183 C6H14N2O 86.27 −2.52 N-Acetylputrescine
134 6.990 (M+Na)+ 175.0989 198.0882 C11H13NO 82.86 4.87 N-Acetyltranylcypromine
135 7.539 (M+H)+ 216.1268 217.1341 C13H16N2O 85.32 −2.70 Nb-Acetyl-Nb-
methyltryptamine
136 8.747 (M+H)+ 135.0686 136.0759 C8 H9 N O 87.70 −1.39 N-Benzylformamide
137 9.361 (M+NH4)+ 242.1275 260.1613 C11H18N2O4 97.30 −3.29 N-Hydroxypentobarbital
138 19.799 (M+Na)+ 484.3385 507.3275 C23H44N6O5 96.28 −2.34 N-tert-Butyloxycarbonyl-
deacetyl-leupeptin
139 19.253 (M+H)+ 129.1519 130.1592 C8H19N 99.07 −1.35 Octylamine*
140 15.006 (M+H)+ 255.2568 256.2641 C16H33NO 95.59 −2.40 Palmitic amide*
141 9.281 (M+H)+ 135.0795 136.0868 C7H9N3 94.18 0.93 p-Aminobenzamidine
142 10.483 (M+H)+ 434.2643 435.2716 C21H34N6O4 92.06 −0.34 Phe Arg Leu
143 8.862 (M+NH4)+ 321.1695 339.2035 C16H23N3O4 92.71 −2.04 Phe Gly Val
144 9.361 (M+NH4)+ 406.2583 424.2921 C21H34N4O4 99.62 −0.75 Phe Lys Leu
145 12.812 (M+H)+ 243.1991 244.2065 C17H25N 85.35 −1.83 Phencyclidine
146 18.627 (M+H)+ 123.9925 124.9998 C2H5O4P 99.77 0.25 Phosphonoacetaldehyde
147 7.154 (M+Na)+ 542.2482 565.2379 C23H43O12P 83.84 1.95 PI(14:1(9Z)/0:0)
148 8.073 (M+H)+ 245.1633 246.1708 C13H19N5 80.56 3.12 Pinacidil
149 7.633 (M+NH4)+ 256.0588 274.0926 C11H12O7 98.80 −2.01 Piscidic Acid
150 9.364 (M+Na)+ 162.1400 185.1293 C12H18 84.10 4.97 Pregeijerene
151 7.517 (M+H)+ 186.1008 187.1084 C8H14N2O3 84.73 −1.94 Pro Ala
152 6.991 (M+H)+ 326.1598 327.1669 C14H22N4O5 90.54 −2.52 Pro Asn Pro
153 6.934 (M+H)+ 371.2166 372.2239 C16H29N5O5 83.53 0.79 Pro Gln Lys
154 7.164 (M+H)+ 340.1752 341.1822 C15H24N4O5 92.07 −1.60 Pro Gln Pro
155 7.402 (M+H)+ 269.1378 270.1451 C12H19N3O4 99.48 −1.05 Pro Gly Pro
156 7.129 (M+H)+ 212.1165 213.1239 C10H16N2O3 83.55 −2.05 Pro Pro
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157 6.930 (M+H)+ 269.1372 270.1446 C12H19N3O4 84.07 1.16 Pro Pro Gly
158 8.222 (M+H)+ 375.1797 376.1867 C19H25N3O5 90.59 −0.64 Pro Pro Tyr
159 5.570 (M+H)+ 434.2276 435.2349 C20H30N6O5 94.18 0.48 Pro Tyr Arg
160 7.417 (M+H)+ 375.1785 376.1861 C19H25N3O5 93.97 2.32 Pro Tyr Pro
161 8.854 (M+Na)+ 217.1824 240.1717 C15H23N 85.69 2.86 Prolintane
162 7.820 (M+H)+ 253.1067 254.1140 C11H15N3O4 85.96 −1.67 Pyricarbate
163 5.311 (M+NH4)+ 183.0901 201.1237 C9H13NO3 90.47 −3.06 Racepinephrine
164 7.516 (M+H)+ 207.0900 208.0972 C11H13NO3 85.18 −2.13 Rhexifoline
165 8.534 (M+H)+ 244.1584 245.1653 C15H20N2O 88.37 −3.31 Rhombifoline
166 9.862 (M+H)+ 122.1099 123.1172 C9H14 86.97 −3.18 Santene*
167 14.655 (M+H)+ 299.2829 300.2901 C18H37NO2 95.29 −1.68 Sphingosine
168 19.924 (M+H)+ 213.2457 214.2530 C14H31N 99.64 −0.40 Tetradecylamine*
169 19.831 (M+H)+ 370.1547 371.1620 C21H26N2S2 93.67 −2.66 Thioridazine
170 4.410 (M+H)+ 346.2212 347.2284 C15H30N4O5 80.69 1.11 Thr Val Lys
171 7.568 (M+Na)+ 493.3240 516.3131 C28H47NO4S 87.00 −2.91 Tiamulin
172 7.166 (M+H)+ 253.1068 254.1142 C12H11N7 83.69 3.12 Triamterene
173 6.352 (M+NH4)+ 184.0489 202.0827 C7H8N2O4 98.31 −2.85 Trimidox
174 9.211 (M+H)+ 141.1154 142.1228 C8H15NO 84.62 −0.41 Tropine
175 7.102 (M+H)+ 415.1856 416.1930 C20H25N5O5 83.43 −0.12 Trp Asn Pro
176 7.010 (M+Na)+ 418.1850 441.1747 C20H26N4O6 80.39 0.59 Trp Asp Val
177 7.210 (M+Na)+ 372.1803 395.1694 C19H24N4O4 81.48 −1.36 Trp Pro Ala
178 7.817 (M+NH4)+ 303.1583 321.1923 C16H21N3O3 96.76 −0.18 Tryptophyl-Valine
179 8.506 (M+NH4)+ 423.2000 441.2342 C20H29N3O7 88.19 1.20 Tyr Ile Glu
180 8.450 (M+NH4)+ 396.2002 414.2345 C18H28N4O6 90.22 1.70 Tyr Ser Lys
181 6.721 (M+Na)+ 516.2543 539.2431 C25H36N6O4S 80.47 −4.67 Udenafil
182 7.666 (M+NH4)+ 387.2258 405.2597 C20H29N5O3 80.07 3.07 Urapidil
183 6.933 (M+H)+ 346.1489 347.1562 C13H22N4O7 81.66 −0.18 Val Asp Asn
184 7.580 (M+H)+ 401.2058 402.2131 C20H27N5O4 82.27 1.29 Val His Phe
185 7.655 (M+H)+ 466.2214 467.2286 C25H30N4O5 93.34 0.48 Val Trp Tyr
186 7.189 (M+H)+ 254.1385 255.1458 C11H18N4O3 98.02 −2.38 Valyl-Histidine
187 9.275 (M+NH4)+ 202.0745 220.1084 C11H10N2O2 86.30 −1.26 Vasicinone
188 8.958 (M+H)+ 199.1326 200.1399 C9H17N3O2 82.59 −2.81 Vinyl-L-NIO
189 5.660 (M+NH4)+ 157.0856 175.1194 C6H11N3O2 98.32 −3.12 V-PYRRO/NO
190 15.142 (M+H)+ 229.2410 230.2483 C14H31NO 84.30 −1.90 Xestoaminol C*
191 17.087 (M+H)+ 115.0461 116.0534 C5H9NS 94.29 −4.73 xi-2,5-Dihydro-2,4-
dimethylthiazole
192 10.173 (M+H)+ 374.0342 375.0411 C17H12Cl2N4O2 82.26 −1.30 α,4-Dihydroxytriazolam
193 14.599 (M+NH4)+ 222.1991 240.2329 C15H26O 97.50 −3.28 β-Caryophyllene Alcohol*
*Indicate the metabolites that found similarly from pHMG extract under second evaluation screening. RT=Retention time, 
DB=Database, LC-MS=Liquid chromatography-mass spectrometry, QTOF=Quadrupole time-of-flight
Table-3: (Continued)
macronutrient classification (Figure-2d). The five 
groups of macronutrients are comprised oligosac-
charides, peptides, lipids, nucleosides, and second-
ary metabolites. There were 192 and 42 metabolites 
identified from eHMG and pHMG extracts (Tables-3 
and 4), respectively. The differences in the type of 
metabolites between eHMG and pHMG extracts have 
further supported the preference of the type of metab-
olites toward each extraction method. Among the 
macronutrients, eHMG extraction method can extract 
mostly secondary metabolites, followed by peptides, 
oligosaccharides, lipids, and nucleosides (Figure-2d). 
The primary metabolites obtained from this study sup-
port the finding from the previous proximate analysis 
of EBN, which protein is the highest composition fol-
lowed by carbohydrates and lipids [2,36,37].
The presence of secondary metabolites could 
most probably explain the recuperative and therapeu-
tic effects of EBN. The secondary metabolite with the 
identity of O2-vinyl 1-(pyrrolidin-1-yl)diazen-1-ium-
1,2-diolate (V-PYRRO/nitric oxide [NO]) was found 
in eHMG extract (Table-3). This secondary metabolite 
acts as NO donor and delivers NO specifically after 
metabolism by cytochrome P450 in hepatocytes with-
out affecting the NO-sensitive tissues as well as sys-
tolic blood pressure [38]. The in vivo study done by Li 
et al. [39] showed that V-PYRRO/NO is able to protect 
the hindrance to renal congestion and lipid peroxidation 
from acetaminophen-induced nephrotoxicity in mice. 
In addition, V-PYRRO/NO can protect against high-fat 
diet (HFD)-induced liver steatosis and insulin resistance 
without affecting the mitochondria biogenesis [40]. 
Interestingly, Zhang et al. [41] showed that EBN could 
prevent HFD-induced insulin resistance by regulating 
the transcriptional changes in insulin signaling genes. 
Hence, the presence of V-PYRRO/NO in EBN may 
explain the protective effect of EBN against the HFD-
induced damages. In short, from this study, it is believed 
that the study on secondary metabolites profiling in 
EBN in the future is crucial and not to be neglected.
A polysaccharide with an identity of chondroitin 
was identified from the first screening of eHMG extract 
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Ion Mass m/z Molecular 
formula




1 19.793 (M+Na)+ 484.3396 507.3290 C27H48O7 96.12 0.87 (25S)-5alpha-cholestan-3beta,4
beta,6alpha,8beta,15alpha,16b
eta,26-heptol
2 3.780 (M+H)+ 99.0322 100.0394 C4H5NO2 86.24 −1.50 (R)-Dihydromaleimide
3 14.655 (M+NH4)+ 168.1881 186.2219 C12H24 98.94 −2.06 1-Dodecene*
4 19.883 (M+H)+ 241.2768 242.2840 C16H35N 86.03 0.67 1-Hexadecylamine
5 17.082 (M+H)+ 203.0807 204.0878 C9H17NS2 93.79 −2.07 1-Isothiocyanato-7-(methylthio)
heptane* 
6 15.586 (M+H)+ 115.0457 116.0530 C5H9NS 99.79 −1.42 1-Isothiocyanatobutane*
7 19.896 (M+NH4)+ 392.4383 410.4722 C28H56 98.76 −0.37 1-Octacosene* 
8 17.084 (M+H)+ 171.1085 172.1157 C9H17NS 96.61 −1.92 2,5-Dihydro-4,5-dimethyl-2-(1-
methylpropyl)thiazole*
9 18.737 (M+H)+ 170.1303 171.1375 C10H18O2 84.98 2.15 2,6-Dimethyl-3,7-octadiene-2,6-
diol
10 7.676 (M+NH4)+ 256.1315 274.1653 C13H20O5 98.83 −1.55 2-[4-(3-Hydroxypropyl)-
2-methoxyphenoxy]-1,3-
propanediol
11 7.678 (M+H)+ 113.0845 114.0918 C6H11NO 98.61 −3.80 2-Acetylpyrrolidine*
12 14.532 (M+H)+ 105.0790 106.0863 C4H11NO2 84.69 −0.41 2-Amino-2-methyl-1,3-
propanediol
13 9.461 (M+H)+ 144.0422 145.0493 C6H8O4 95.91 0.31 2-Hydroxy-2-(hydroxymethyl)-
2H-pyran-3(6H)-one
14 9.859 (M+H)+ 101.0844 102.0916 C5H11NO 96.89 −3.15 2-methylbutanal oxime
15 8.921 (M+H)+ 209.1423 210.1496 C12H19NO2 84.38 −3.50 3,4-dimethoxymethamphetamine
16 19.503 (M+NH4)+ 135.0564 153.0902 C7H7N2O 82.59 −4.21 4-(Hydroxymethyl)
benzenediazonium(1+)
17 7.839 (M+H)+ 125.0839 126.0912 C7H11NO 87.69 1.30 4-Ethyl-2,5-dimethyloxazole
18 6.992 (M+H)+ 129.0430 130.0503 C5H7NO3 82.11 −3.43 4-Oxoproline*
19 8.905 (M+H)+ 153.1156 154.1227 C9H15NO 95.68 −1.34 5-Butyl-2-ethyloxazole
20 7.182 (M+NH4)+ 165.1155 183.1491 C10H15NO 82.05 −0.72 5-Methyl-2-(1-pyrrolidinyl)-2-
cyclopenten-1-one* 
21 16.002 (M+NH4)+ 250.2302 268.2640 C17H30O 85.38 −2.25 9S,10R-Epoxy-3Z,6Z-
octadecadiene* 
22 19.912 (M+NH4)+ 364.4070 382.4409 C26H52 99.67 −0.34 9Z-Hexacosene* 
23 5.021 (M+H)+ 135.0550 136.0622 C5H5N5 86.53 −3.53 Adenine* 
24 5.761 (M+H)+ 226.1066 227.1139 C9H14N4O3 92.45 0.04 Alanyl-Histidine* 
25 18.616 (M+H)+ 142.0013 143.0084 C4H2N2O4 80.18 0.76 Alloxan
26 5.765 (M+H)+ 109.0641 110.0713 C5H7N3 83.73 −1.28 Brunfelsamidine* 
27 7.804 (M+NH4)+ 922.4758 940.5092 C44H74O20 95.22 1.67 Capsianoside VI
28 19.762 (M+NH4)+ 747.4789 765.5129 C38H69NO13 85.36 −2.63 Clarithromycin
29 17.082 (M+H)+ 127.1363 128.1435 C8H17N 86.72 −1.61 Coniine*
30 19.949 (M+NH4)+ 703.4523 721.4865 C36H65NO12 80.50 −2.29 Erythromycin D
31 13.733 (M+Na)+ 270.1830 293.1723 C15H26O4 86.19 0.32 Ethylene brassylate
32 19.854 (M+NH4)+ 240.2452 258.2791 C16H32O 85.17 0.68 hexadeca-9-en-1-ol
33 19.781 (M+H)+ 101.1201 102.1274 C6H15N 87.12 3.51 Hexylamine* 
34 18.616 (M+H)+ 298.1537 299.1607 C15H18N6O 83.14 1.86 Iso-Olomoucine* 
35 8.676 (M+NH4)+ 268.1312 286.1649 C14H20O5 80.46 −0.63 Kamahine C* 
36 3.375 (M+Na)+ 383.1426 406.1318 C14H25NO11 94.48 0.36 Lacto-N-biose I* 
37 19.300 (M+H)+ 129.1511 130.1585 C8H19N 83.91 4.67 Octylamine* 
38 14.588 (M+H)+ 255.2565 256.2637 C16H33NO 98.75 −1.08 Palmitic amide* 
39 9.858 (M+H)+ 122.1096 123.1169 C9H14 85.95 −0.42 Santene* 
40 19.911 (M+H)+ 213.2457 214.2530 C14H31N 98.18 −0.32 Tetradecylamine* 
41 19.838 (M+H)+ 229.2406 230.2478 C14H31NO 97.56 0.01 Xestoaminol C* 
42 14.568 (M+NH4)+ 222.1988 240.2326 C15H26O 98.81 −2.08 β-Caryophyllene Alcohol* 
*Indicate the metabolites that found similarly from eHMG extract under second evaluation screening. RT=Retention time, 
DB=Database, LC-MS=Liquid chromatography-mass spectrometry, QTOF=Quadrupole time-of-flight
(Table-1), in which the discovery of water-soluble 
chondroitin is similar to the finding of Nakagawa et al. 
in EBN [42]. Chondroitin is a glycosaminoglycan that 
acts as a chondroprotective agent for the treatment 
of OA. OA is the lesion of articular cartilage caused 
by trauma. Since chondroitin is an essential proteo-
glycan in cartilage, it acts on OA by stimulates the 
cartilage repair through enhancing the production of 
the extracellular matrix of cartilage. Besides, chondroi-
tin helps to maintain the viscosity of the synovial fluid 
to lubricate the joint and therefore reducing the pain 
of the patient. Furthermore, chondroitin suppresses 
the inflammatory cytokines such as interleukin-1β that 
induce the release of matrix metalloproteinases and 
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aggrecanases which cause the degradation of the car-
tilage [43,44]. In an in vitro study done by Chua et al. 
on the effects of EBN to OA [17], the authors reported 
that EBN can protect articular cartilage from further 
deterioration by reducing inflammation and enzymatic 
lesions process and enhancing the cartilage formation 
simultaneously. Therefore, the effects of EBN on OA 
might be contributed by chondroitin.
Conclusion
There was no single extraction method could 
provide optimal conditions in extracting all the 
metabolites from EBN. Therefore, complementary 
extraction methods should be used in parallel when 
broader metabolite profiles are required. eHMG 
extraction method was selected as the ideal extraction 
method for untargeted profiling the type of polar 
metabolites in EBN. This is because the number and 
the type of metabolites detected are the highest in 
eHMG extracts among the four evaluated extraction 
methods. Furthermore, the presence of key metabo-
lites of sialic acid has further defined the suitability of 
eHMG extraction method. Therefore, the findings in 
this study could offer great potential for enhancement 
in the industrial EBN extraction process and hence 
improve the overall EBN yield and bioactivities. 
Nevertheless, the validation of the structure elucida-
tion and functional assays of interesting metabolites 
shall be carried out in the future.
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